+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Leukocyte Antigens Typing Market by Product Type (Instruments, Reagents & Consumables, Software & Services), Application (Disease Association Studies, Forensic Studies, Pharmacogenomics), End User - Global Forecast 2025-2030- Product Image
Human Leukocyte Antigens Typing Market by Product Type (Instruments, Reagents & Consumables, Software & Services), Application (Disease Association Studies, Forensic Studies, Pharmacogenomics), End User - Global Forecast 2025-2030- Product Image
Sale

Human Leukocyte Antigens Typing Market by Product Type (Instruments, Reagents & Consumables, Software & Services), Application (Disease Association Studies, Forensic Studies, Pharmacogenomics), End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6160594
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Leukocyte Antigens Typing Market grew from USD 1.43 billion in 2024 to USD 1.51 billion in 2025. It is expected to continue growing at a CAGR of 5.66%, reaching USD 1.99 billion by 2030.

Unveiling the transformative importance of human leukocyte antigen typing as a cornerstone in precision diagnostics and transplantation strategy planning

Human leukocyte antigen typing has emerged as a pivotal tool in the personalization of healthcare by enabling precise matching in transplantation and by informing risk assessments in disease association studies. This introduction explores the biological underpinnings of HLA polymorphism and the critical role that accurate allele identification plays in preventing graft rejection, optimizing pharmacogenomic interventions, and advancing forensic investigations.

By tracing the evolution from serological assays to high-resolution molecular techniques, this section sets the stage for understanding how HLA typing undergirds both routine clinical diagnostics and cutting-edge research applications. The interplay between scientific innovation, regulatory standards, and clinical demand drives continuous refinement of typing methodologies. As precision medicine takes center stage, HLA typing stands as a foundational discipline that shapes patient outcomes, informs drug development pipelines, and catalyzes translational research across multiple domains.

Examining the paradigm shift driven by next generation sequencing innovations and regulatory evolutions in HLA typing landscapes worldwide

The landscape of human leukocyte antigen typing is undergoing a remarkable transformation fueled by advancements in next-generation sequencing, automation, and bioinformatics integration. High-throughput platforms now deliver unprecedented resolution at reduced turnaround times, enabling laboratories to transition from low-resolution group typing to detailed allele-level characterization. This shift not only improves transplant compatibility assessments but also expands applications in pharmacogenomics and disease association studies.

Regulatory frameworks have adapted in parallel, introducing streamlined pathways for clinical validation while enforcing stringent quality management systems. These changes have lowered entry barriers for innovative technologies, encouraging collaboration between academic centers, diagnostic manufacturers, and contract research organizations. As digital transformation takes hold, the integration of cloud-based analysis tools and AI-driven interpretation pipelines is further accelerating throughput and consistency, promising a new era of rapid, data-rich HLA typing protocols.

Assessing the multifaceted influence of newly implemented United States tariffs on procurement costs and supply chain resilience in HLA typing ecosystem

The introduction of increased United States tariffs in 2025 has created a ripple effect across the global human leukocyte antigen typing supply chain, impacting the procurement of sequencers, reagents, and laboratory consumables. Organizations reliant on imports have reported escalated operational costs, prompting many to renegotiate supplier agreements or diversify sourcing strategies to mitigate financial pressures.

In response, leading instrument manufacturers and reagent providers have intensified efforts to localize production and optimize logistical pipelines. While some laboratories have absorbed additional expenses without compromising service levels, others are accelerating adoption of cost-efficient assay formats or exploring reagent rental programs. These tactical adjustments underscore the need for agile supply chain management and proactive stakeholder communication as tariffs continue to reshape cost structures and competitive dynamics in HLA typing.

Highlighting critical segmentation revelations across technology platforms applications end users and product type classifications shaping HLA typing market dynamics

Analyzing the market through a technology-centric lens reveals that next generation sequencing platforms are rapidly gaining prominence due to their scalability and depth of allele resolution, while PCR sequence specific oligonucleotide probes and PCR sequence specific primers maintain a strong presence in medium-throughput settings. Sanger sequencing continues to serve niche applications where established protocols and legacy workflows prevail.

From an application standpoint, disease association studies are increasingly leveraging high-resolution typing data to uncover novel genetic predispositions, while forensic investigations depend on specialized primer-based methods for precise individual identification. Pharmacogenomics has surfaced as a critical driver for personalized drug therapy, and transplantation remains the primary revenue source, demanding continuous improvements in matching accuracy.

End users such as hospitals and diagnostic laboratories are investing in integrated platforms to streamline clinical workflows, whereas research and academic institutes emphasize flexibility and depth of analysis. Transplant centers, in turn, require rapid turnaround and robust data interpretation to support time-sensitive decision-making.

Product segmentation highlights the evolution of comprehensive instrument and software suites that offer end-to-end solutions, alongside modular kits and reagents designed for specific assay components. This dual structure caters to fully automated laboratory environments and to facilities that prefer bespoke reagent packages, reflecting a nuanced approach to market coverage.

Delving into regional disparities and growth drivers across the Americas Europe Middle East Africa and Asia Pacific HLA typing sectors

Regional analysis indicates that the Americas continue to lead in HLA typing adoption, propelled by substantial investments in genomic infrastructure and well-established clinical trial frameworks. The United States, in particular, has seen accelerated uptake of high-resolution sequencing technologies, supported by favorable reimbursement environments and robust academic-industry collaborations.

In Europe, Middle East & Africa, a heterogeneous landscape emerges, where mature markets benefit from harmonized regulatory directives and centralized reference laboratories, while emerging economies are driving expansion through public health initiatives and cross-border partnerships. Demand for transplantation services and forensic capabilities remains a consistent growth catalyst across the region.

The Asia-Pacific region is distinguished by rapidly increasing government funding for genomics research, a growing network of private diagnostic chains, and escalating interest in pharmacogenomic profiling. Local manufacturing hubs are evolving to address cost sensitivities, and strategic alliances with global technology providers are accelerating technology transfer and capacity building across major economies such as China, Japan, and India.

Revealing competitive maneuvers strategic alliances and innovation pipelines that define the leadership landscape in HLA typing development

The competitive landscape of human leukocyte antigen typing is defined by a blend of established diagnostic equipment manufacturers and agile biotechnology firms. Leading stakeholders are expanding their portfolios through strategic acquisitions of niche assay developers and forging partnerships with genomics platforms to enhance end-to-end offerings. Collaborative ventures with academic institutions and contract research organizations are further solidifying their presence in emerging application areas.

R&D pipelines are heavily oriented toward multiplexed assay formats, integrated software solutions that streamline data interpretation, and novel chemistries that reduce reagent consumption. Some entities are piloting subscription-based service models to deliver reagents and data analysis as a bundled solution, fostering deeper customer engagement. Competitive differentiation increasingly hinges on the ability to demonstrate clinical utility, regulatory compliance, and efficient supply chain management, as buyers seek reliable, validated systems for both routine diagnostics and advanced research.

Proposing strategic initiatives operational optimizations and collaborative frameworks to accelerate growth in the dynamic HLA typing arena

Industry leaders should prioritize the establishment of flexible supply chain networks that incorporate local manufacturing partners to mitigate exposure to international tariffs and logistical disruptions. Concurrently, investing in automation and cloud-based bioinformatics platforms will enhance throughput and consistency, enabling laboratories to balance high-resolution demands with resource efficiency.

Developing strategic partnerships with academic and clinical research centers can accelerate validation of novel assay formats and strengthen adoption in transplantation and pharmacogenomics. Organizations should also explore subscription or reagent rental models as a means to streamline procurement processes and foster long-term customer loyalty. Lastly, maintaining active engagement with regulatory bodies will ensure early alignment with evolving quality standards and facilitate smoother market entry for innovative technologies.

Outlining the rigorous multi tiered research approach expert engagements and data validation techniques underpinning this HLA typing analysis

This analysis is grounded in a robust, multi-tiered research framework combining primary interviews with key opinion leaders, laboratory directors, and procurement executives, alongside a comprehensive review of regulatory filings, patent databases, and peer-reviewed publications. Quantitative data was triangulated across multiple vendor reports, industry white papers, and conference proceedings to ensure consistency and reliability.

Secondary research involved mapping technology pipelines, assessing clinical validation studies, and synthesizing information from accreditation bodies. All findings were rigorously validated through follow-up consultations with subject matter experts and cross-checked against industry benchmarks. This meticulous approach ensures that the insights presented reflect the current state of technological innovation, competitive dynamics, and regional market drivers within the human leukocyte antigen typing domain.

Synthesizing core insights future outlook and the imperative for innovation adoption in human leukocyte antigen typing sphere

In conclusion, human leukocyte antigen typing stands at the nexus of scientific innovation and clinical application, with advances in high-resolution sequencing, automation, and bioinformatics reshaping the market. Tariff-driven supply chain realignments underscore the importance of diversified procurement strategies and localized manufacturing capabilities. Segmentation analysis reveals that technology, application, and end-user dynamics are intricately linked, driving tailored solutions for transplantation, disease association research, pharmacogenomics, and forensic investigations.

Regional trends highlight leadership in the Americas, complemented by targeted growth in Europe, Middle East & Africa, and rapid expansion across Asia-Pacific. Competitive intensity is high as companies vie for differentiation through partnerships, product innovation, and flexible service models. The recommendations outlined herein provide a roadmap for stakeholders to navigate evolving regulatory landscapes, optimize operational efficiencies, and capitalize on emerging growth opportunities in this critical field.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Instruments
      • Flow Cytometers
      • PCR Systems
      • Sequencing Instruments
        • Next-Generation Sequencers
        • Sanger Sequencers
    • Reagents & Consumables
      • Assay Consumables
      • NGS & Sanger Sequencing Kits / Library Prep Kits
      • PCR Reagents
    • Software & Services
  • Application
    • Disease Association Studies
    • Forensic Studies
    • Pharmacogenomics
    • Transplantation
  • End User
    • Hospitals & Diagnostic Labs
    • Research & Academic Institutes
    • Transplant Centers
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • CareDx, Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson and Company (BD)
  • Immucor, Inc.
  • Omixon Inc.
  • TBG Diagnostics Ltd.
  • BAG Diagnostics GmbH
  • Creative Biolabs
  • Fujirebio, Inc.
  • Pacific Biosciences (PacBio)
  • Biofortuna Ltd.
  • Takara Bio, Inc.
  • Hologic, Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Eurofins Scientific
  • Beckman Coulter Life Sciences
  • Oxford Nanopore Technologies Plc
  • HistoGenetics LLC
  • Bruker Corporation

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of AI-driven bioinformatics pipelines improving allele resolution in complex HLA typing workflows
5.2. Adoption of high-throughput next-generation sequencing assays enabling population-scale HLA diversity profiling for immunogenetics research
5.3. Transition from Sanger sequencing to long-read technologies enhancing accuracy in phasing HLA haplotypes for graft compatibility
5.4. Growth of point-of-care microfluidic HLA typing assays accelerating on-site donor-recipient matching in transplant centers
5.5. Implementation of standardized HLA typing quality metrics by regulatory bodies driving laboratory accreditation and compliance
5.6. Development of CRISPR-based diagnostics for ultra-rapid HLA allele detection reducing turnaround time in urgent transplant cases
5.7. Expansion of cloud-enabled HLA registry platforms facilitating real-time global donor matching and diversity analytics
5.8. Increased collaboration between biotechnology firms and academic consortia to map rare HLA variants across diverse populations
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Leukocyte Antigens Typing Market, by Product Type
8.1. Introduction
8.2. Instruments
8.2.1. Flow Cytometers
8.2.2. PCR Systems
8.2.3. Sequencing Instruments
8.2.3.1. Next-Generation Sequencers
8.2.3.2. Sanger Sequencers
8.3. Reagents & Consumables
8.3.1. Assay Consumables
8.3.2. NGS & Sanger Sequencing Kits / Library Prep Kits
8.3.3. PCR Reagents
8.4. Software & Services
9. Human Leukocyte Antigens Typing Market, by Application
9.1. Introduction
9.2. Disease Association Studies
9.3. Forensic Studies
9.4. Pharmacogenomics
9.5. Transplantation
10. Human Leukocyte Antigens Typing Market, by End User
10.1. Introduction
10.2. Hospitals & Diagnostic Labs
10.3. Research & Academic Institutes
10.4. Transplant Centers
11. Americas Human Leukocyte Antigens Typing Market
11.1. Introduction
11.2. Canada
11.3. United States
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Human Leukocyte Antigens Typing Market
12.1. Introduction
12.2. Sweden
12.3. Germany
12.4. Finland
12.5. Qatar
12.6. Israel
12.7. United Kingdom
12.8. Turkey
12.9. Saudi Arabia
12.10. Nigeria
12.11. Italy
12.12. Switzerland
12.13. Denmark
12.14. Netherlands
12.15. Egypt
12.16. France
12.17. South Africa
12.18. Poland
12.19. Spain
12.20. Norway
12.21. Russia
12.22. United Arab Emirates
13. Asia-Pacific Human Leukocyte Antigens Typing Market
13.1. Introduction
13.2. Thailand
13.3. Philippines
13.4. Vietnam
13.5. China
13.6. Singapore
13.7. Japan
13.8. South Korea
13.9. Malaysia
13.10. Indonesia
13.11. India
13.12. Taiwan
13.13. Australia
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Thermo Fisher Scientific Inc.
14.3.2. Bio-Rad Laboratories, Inc.
14.3.3. QIAGEN N.V.
14.3.4. CareDx, Inc.
14.3.5. Illumina, Inc.
14.3.6. F. Hoffmann-La Roche Ltd.
14.3.7. Becton, Dickinson and Company (BD)
14.3.8. Immucor, Inc.
14.3.9. Omixon Inc.
14.3.10. TBG Diagnostics Ltd.
14.3.11. BAG Diagnostics GmbH
14.3.12. Creative Biolabs
14.3.13. Fujirebio, Inc.
14.3.14. Pacific Biosciences (PacBio)
14.3.15. Biofortuna Ltd.
14.3.16. Takara Bio, Inc.
14.3.17. Hologic, Inc.
14.3.18. Abbott Laboratories
14.3.19. Agilent Technologies, Inc.
14.3.20. Eurofins Scientific
14.3.21. Beckman Coulter Life Sciences
14.3.22. Oxford Nanopore Technologies Plc
14.3.23. HistoGenetics LLC
14.3.24. Bruker Corporation
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. HUMAN LEUKOCYTE ANTIGENS TYPING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 12. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 14. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 20. HUMAN LEUKOCYTE ANTIGENS TYPING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 21. HUMAN LEUKOCYTE ANTIGENS TYPING MARKET: RESEARCHAI
FIGURE 22. HUMAN LEUKOCYTE ANTIGENS TYPING MARKET: RESEARCHSTATISTICS
FIGURE 23. HUMAN LEUKOCYTE ANTIGENS TYPING MARKET: RESEARCHCONTACTS
FIGURE 24. HUMAN LEUKOCYTE ANTIGENS TYPING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY NEXT-GENERATION SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY NEXT-GENERATION SEQUENCERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SANGER SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SANGER SEQUENCERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY ASSAY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY ASSAY CONSUMABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY NGS & SANGER SEQUENCING KITS / LIBRARY PREP KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY NGS & SANGER SEQUENCING KITS / LIBRARY PREP KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY DISEASE ASSOCIATION STUDIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY DISEASE ASSOCIATION STUDIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY FORENSIC STUDIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY FORENSIC STUDIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 72. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 73. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 74. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 75. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 76. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 77. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 78. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 79. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 80. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 81. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. CANADA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 98. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 100. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 101. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 102. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 103. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 104. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 105. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 106. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 107. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. MEXICO HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 148. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 149. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 150. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 151. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 152. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 153. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 154. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 155. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 156. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 157. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. SWEDEN HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 162. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 163. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 164. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 165. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 166. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 167. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. GERMANY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 172. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 173. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 174. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 175. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 176. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 177. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 178. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 179. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 180. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 181. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. FINLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 186. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 187. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 188. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 189. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 190. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 191. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 192. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 193. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. QATAR HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 196. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 197. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 198. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 199. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 200. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 201. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 202. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 203. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. ISRAEL HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 220. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 221. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 222. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 223. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 224. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 225. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 226. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 227. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 228. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 229. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. TURKEY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 240. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SAUDI ARABIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 246. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 247. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 248. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 249. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 250. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 251. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. NIGERIA HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 256. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 257. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 258. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 259. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 260. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 261. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 262. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 263. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 264. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 265. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. ITALY HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 273. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 274. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 275. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 276. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 277. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. SWITZERLAND HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 280. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 281. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 282. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 283. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 284. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 285. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 286. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030 (USD MILLION)
TABLE 287. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 288. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 289. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. DENMARK HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. NETHERLANDS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 292. NETHERLANDS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 293. NETHERLANDS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 294. NETHERLANDS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 295. NETHERLANDS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 296. NETHERLANDS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY SEQUENCING INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 297. NETHERLANDS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
TABLE 298. NETHERLANDS HUMAN LEUKOCYTE ANTIGENS TYPING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2030

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Human Leukocyte Antigens Typing market report include:
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • CareDx, Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Becton, Dickinson and Company (BD)
  • Immucor, Inc.
  • Omixon Inc.
  • TBG Diagnostics Ltd.
  • BAG Diagnostics GmbH
  • Creative Biolabs
  • Fujirebio, Inc.
  • Pacific Biosciences (PacBio)
  • Biofortuna Ltd.
  • Takara Bio, Inc.
  • Hologic, Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Eurofins Scientific
  • Beckman Coulter Life Sciences
  • Oxford Nanopore Technologies Plc
  • HistoGenetics LLC
  • Bruker Corporation

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.51 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.99 Billion
Compound Annual Growth Rate5.6%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Reports

Human Leukocyte Antigen Typing Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Human Leukocyte Antigen Typing Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 95 Pages
  • Global
From
Preimplantation Genetic Testing Market Report 2025 - Product Image

Preimplantation Genetic Testing Market Report 2025

  • Report
  • 175 Pages
  • Global
From
HLA Typing for Transplant Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F - Product Image

HLA Typing for Transplant Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Blood Group Typing Market Report 2025 - Product Image

Blood Group Typing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
North America Human Leukocyte Antigen Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and service, Technology, and End User - Product Image

North America Human Leukocyte Antigen Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product and service, Technology, and End User

  • Report
  • 172 Pages
  • North America
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.